Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 326

Sort by

Sort Order Select

Journal Articles

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl

Blood (2021) 137 (19): 2634–2645.

https://doi.org/10.1182/blood.2020007512

Published: 2021

Includes: Supplemental data

Journal Articles

The AHR: adaptive evolution or one-off?

Michael H. Kroll

Blood (2019) 134 (26): 2337–2338.

https://doi.org/10.1182/blood.2019003943

Published: 2019

Journal Articles

Paroxysmal Cold Hemoglobinuria Successfully Treated with Complement Inhibition

Sarah A Lau-Braunhut, MD, Hannah Stone, Griffin Collins, MD, Sigbjørn Berentsen, MD PhD, Matt Zinter, MD, Benjamin Braun, MD PhD

Blood (2019) 134 (Supplement_1): 4798.

https://doi.org/10.1182/blood-2019-126365

Published: 2019

Journal Articles

A Population-Based Analysis of Predictors of Survival and Trends in Outcomes of Elderly Patients with Multiple Myeloma (MM)

Vivek Kumar, MD, M.B.,B.S., Meghna Ailawadhi, MD, Mays F Abdulazeez, MBBS, Suman Biswas, MD, Sri Lekha Bodepudi, Leyla Bojanini, MD, Vivek Roy, MD, Taimur Sher, MD, Victoria R. Alegria, Rami Manochakian, MD, Aneel Paulus, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi, MD

Blood (2019) 134 (Supplement_1): 4779.

https://doi.org/10.1182/blood-2019-125156

Published: 2019

Journal Articles

A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)

Shaji K. Kumar, MD, Robert F. Cornell, MD MS, Ola Landgren, MD PhD, Sikander Ailawadhi, MD, Jack P Higgins, PhD, Erin K Willert, Roger Waltzman, MD MBA, Jianchang Lin, PhD, Yuhong Zhang, Anya R Lublinsky, Ajeeta B Dash, PhD, Michael Hanley, Divya Manoharan, Morgan Leichter, Sean Ottinger, Richard J Labotka, John Newcomb, Alexander Vorog, MD

Blood (2019) 134 (Supplement_1): 1867.

https://doi.org/10.1182/blood-2019-125629

Published: 2019

Journal Articles

Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)

Tiziana Vaisitti, PhD, Katti Jessen, PhD, Thanh-Trang Vo, PhD, Mira Ko, Francesca Arruga, PhD, Nicoletta Vitale, PhD, Esteban Braggio, PhD, Arianna Di Napoli, Amy Chadburn, MD, John N. Allan, MD, Richard R. Furman, MD, Langdon L. Miller, Brian J Lanutti, PhD, Silvia Deaglio, MD PhD

Blood (2019) 134 (Supplement_1): 2856.

https://doi.org/10.1182/blood-2019-126827

Published: 2019

Journal Articles

FA Gene Carrier Status Predisposes to Myeloid Neoplasms and Bone Marrow Failure in Adults

Jibran Durrani, Hassan Awada, MD, Wenyi Shen, MD, Cassandra M Kerr, MS, Vera Adema, PhD, Sunisa Kongkiatkamon, Ashwin Kishtagari, MBBS, Samuel Li, Yasunobu Nagata, MD PhD, Sanghee Hong, MD, Aziz Nazha, MD, Bhumika J. Patel, MD, Yogenthiran Saunthararajah, MD, Hetty E. Carraway, MD MBA, Valeria Visconte, PhD, Seth J. Corey, MD, Mikkael A. Sekeres, MD MS, Thomas Laframboise, PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 452.

https://doi.org/10.1182/blood-2019-130142

Published: 2019

Journal Articles

Depletion of Neoplastic CD11b Positive Cells in Jak2 V617F Mutant Mice Reduced Fibrocytes in Bone Marrow and Improved Myelofibrosis

Yoshinori Ozono, MD, Kotaro Shide, MD PhD, Takuro Kameda, MD PhD, Ayako Kamiunten, MD, Yuki Tahira, MD, Masaaki Sekine, MD, Keiichi Akizuki, MD, Kenichi Nakamura, MD, Hisayoshi Iwakiri, MD, Tomonori Hidaka, MD, Yoko Kubuki, MD PhD, Satoru Hasuike, MD PhD, Fumiyo Toyoshima, MD PhD, Akira Sawaguchi, MD PhD, Kenji Nagata, MD PhD, Kazuya Shimoda, MD PhD

Blood (2019) 134 (Supplement_1): 310.

https://doi.org/10.1182/blood-2019-130042

Published: 2019

Journal Articles

Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Paul A. Hamlin, MD, Vasile Musteata, MD PhD, Mamia Zodelava, MD, Steven I Park, MD, Christine Burnett, Kristina Dabovic, PharmD, Eric T Williams, PhD, Jack P Higgins, PhD, Daniel O. Persky, MD

Blood (2019) 134 (Supplement_1): 4098.

https://doi.org/10.1182/blood-2019-129243

Published: 2019

Journal Articles

Clostridium Difficile Infection Among Hematopoietic Stem Cell Transplant Recipients and Subsequent Development of Graft-Versus-Host Disease

Shanee Chung, MD, Yasser Abou Mourad, MD

Blood (2019) 134 (Supplement_1): 4494.

https://doi.org/10.1182/blood-2019-129663

Published: 2019

Journal Articles

Novel Role of Raft-Associated Smoothened (SMO) in AKT Signal Regulation in Diffuse Large B Cell Lymphoma

Nitin Agarwal, PhD, Kranthi Kunkalla, Daniel Bilbao, PhD, Ralf Landgraf, PhD, Francisco Vega, MD PhD

Blood (2019) 134 (Supplement_1): 3972.

https://doi.org/10.1182/blood-2019-121847

Published: 2019

Journal Articles

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

Julien Depaus, Locke J. Bryan, MD, David Ungar, MD, Ilva Dautaj, Nina D. Wagner-Johnston, MD

Blood (2019) 134 (Supplement_1): 5309.

https://doi.org/10.1182/blood-2019-126913

Published: 2019

Journal Articles

Preclinical Development of an Anti-CD38 Antibody-Drug Conjugate for Treatment of Hematological Malignancies

Lingna Li, PhD, Wenyong Tong, PhD, Megan Lau, BS, Katherine Fells, PhD, Tong Zhu, PhD, Yingqing Sun, PhD, Ernest Kovacs, PhD, Alisher Khasanov, PhD, Zheng Yan, PhD, Dalun Deng, PhD, Ken Takeshita, MD, Gunnar F. Kaufmann, PhD, Henry Ji, PhD, Hui Li, PhD, Hong Zhang, PhD

Blood (2019) 134 (Supplement_1): 5621.

https://doi.org/10.1182/blood-2019-132062

Published: 2019

Journal Articles

Preclinical Development of a Bcma Targeting Antibody-Drug Conjugate with Novel Payload for Multiple Myeloma Therapy

Andrew Hau, PhD, Tong Zhu, PhD, Rengang Wang, PhD, Megan Lau, BS, Lingna Li, PhD, Xiaoqing Li, PhD, Yingqing Sun, PhD, Ernest Kovacs, PhD, Alisher Khasanov, PhD, Dalun Deng, PhD, Zheng Yan, PhD, Robert D. Knight, MD, Gunnar F. Kaufmann, PhD, Henry Ji, PhD, Hui Li, PhD, Hong Zhang, PhD

Blood (2019) 134 (Supplement_1): 5623.

https://doi.org/10.1182/blood-2019-132080

Published: 2019

Journal Articles

A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Daniel O. Persky, MD, Vasile Musteata, MD PhD, Mamia Zodelava, MD, Tetiana Perekhrestenko, MD PhD, Adolfo E Diaz, MD, Troy H. Guthrie, Jr., MD, Thomas Strack, MD, Christine Burnett, Sarah Wilson, CCRA, Tara Baetz, MD FRCPC

Blood (2019) 134 (Supplement_1): 5324.

https://doi.org/10.1182/blood-2019-128604

Published: 2019

Journal Articles

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Christine Burnett, Thomas Strack, MD, Tara Lehner, MS, PMP, Jack P Higgins, PhD, Deborah A. Katz, MD, Matthew S. McKinney, MD

Blood (2019) 134 (Supplement_1): 5322.

https://doi.org/10.1182/blood-2019-124890

Published: 2019

Journal Articles

Hematopoietic Stem and Progenitor Cells Manifest Direct Migration Towards Secreted DEK in a CXCR2- and G Protein Signaling-Dependent Manner

Maegan L. Capitano, PhD, Yasser Sammour, Maureen Legendre, Scott Cooper, MS, David Markovitz, MD, Hal E. Broxmeyer, PhD

Blood (2019) 134 (Supplement_1): 1196.

https://doi.org/10.1182/blood-2019-128738

Published: 2019

Journal Articles

Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Blood (2019) 134 (Supplement_1): 2642.

https://doi.org/10.1182/blood-2019-129137

Published: 2019

Journal Articles

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Craig H. Moskowitz, Mariana Bastos-Oreiro, MD PhD, David Ungar, MD, Ilva Dautaj, Matko Kalac, MD PhD

Blood (2019) 134 (Supplement_1): 2807.

https://doi.org/10.1182/blood-2019-128036

Published: 2019

Journal Articles

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Lenalidomide in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Christine Burnett, Gary Gordon, MD PhD, Thomas Strack, MD, Tara Lehner, MS, PMP, Jack P Higgins, PhD, Jason Tache, DO

Blood (2019) 134 (Supplement_1): 1597.

https://doi.org/10.1182/blood-2019-128503

Published: 2019

NARROW

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

The AHR: adaptive evolution or one-off?

Paroxysmal Cold Hemoglobinuria Successfully Treated with Complement Inhibition

A Population-Based Analysis of Predictors of Survival and Trends in Outcomes of Elderly Patients with Multiple Myeloma (MM)

Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)

FA Gene Carrier Status Predisposes to Myeloid Neoplasms and Bone Marrow Failure in Adults

Depletion of Neoplastic CD11b Positive Cells in Jak2 V617F Mutant Mice Reduced Fibrocytes in Bone Marrow and Improved Myelofibrosis

Monotherapy Activity with the First CD20-Targeted Immunotoxin, MT-3724, in Subjects with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Clostridium Difficile Infection Among Hematopoietic Stem Cell Transplant Recipients and Subsequent Development of Graft-Versus-Host Disease

Novel Role of Raft-Associated Smoothened (SMO) in AKT Signal Regulation in Diffuse Large B Cell Lymphoma

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

Preclinical Development of an Anti-CD38 Antibody-Drug Conjugate for Treatment of Hematological Malignancies

Preclinical Development of a Bcma Targeting Antibody-Drug Conjugate with Novel Payload for Multiple Myeloma Therapy

A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Hematopoietic Stem and Progenitor Cells Manifest Direct Migration Towards Secreted DEK in a CXCR2- and G Protein Signaling-Dependent Manner

Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Lenalidomide in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only